Epidermal growth factor receptor expression in acute myelogenous leukaemia is associated with clinical prognosis

Hematological Oncology

Volumn 30, Issue 2, 2012, Pages 89-97

  Sun, Jun Zhong ^a   Lu, Ying ^b   Xu, Yin ^c   Liu, Fang ^a   Li, Fu Quan ^c   Wang, Quan Li ^b   Wu, Chu Tse ^c   Hu, Xian Wen ^d   Duan, Hai Feng ^c  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^d BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

Author keywords

Clinical prognosis; Epidermal growth factor receptor; Hematological malignancies

Indexed keywords

CETUXIMAB; CYTARABINE; DAUNORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SCREENING; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84861829116     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.1002     Document Type: Article

References (27)

1. Shepard HM, Brdlik CM, Schreiber H. Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J Clin Invest 2008; 118: 3574-3581.
2. Levitzki A. EGF receptor as a therapeutic target. Lung Cancer 2003; 41(Suppl 1): S9-S14.
3. Saltz LB, Meropol NJ, Loehrer PJ, Sr., Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208.
4. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-2158.
5. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19: 3267-3279.
6. Stegmaier K, Corsello SM, Ross KN, Wong JS, Deangelo DJ, Golub TR. Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood 2005; 106: 2841-2848.
7. Walz TM, Malm C, Wasteson A. Expression of the transforming growth factor alpha protooncogene in differentiating human promyelocytic leukemia (HL-60) cells Cancer Res 1993; 53: 191-196.
8. Lindhagen E, Eriksson A, Wickström M, et al. Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia. Eur J Haematol 2008; 81: 344-353.
9. Chan G, Pilichowska M. Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non small-cell lung cancer. Blood 2007; 110: 1079-1080.
10. Pitini V, Arrigo C, Altavilla G. Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer. J Clin Oncol 2008; 26: 3645-3646.
11. Boehrer S, Adès L, Braun T, et al. Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood 2008; 111: 2170-2180.
12. Boehrer S, Adès L, Galluzzi L, et al. Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison. Biochem Pharmacol 2008; 76: 1417-1425.
13. Ryan MA, Nattamai KJ, Xing E, et al. Pharmacological inhibition of EGFR signaling enhances G-CSF-induced hematopoietic stem cell mobilization. Nat Med 2010; 16: 1141-1146.
14. Mahtouk K, Jourdan M, De Vos J, et al. An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis. Blood 2004; 103: 1829-1837.
15. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164-172.
16. Yuan Y, Zhou L, Miyamoto T, et al. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci USA 2001; 98: 10398-10403.
17. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137.
18. Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 2007; 98: 1275-1280.
19. Kurai J, Chikumi H, Hashimoto K, et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 2007; 13: 1552-1561.
20. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37: S3-S8.
21. Rickman OB, Vohra PK, Sanyal B, et al. Analysis of ErbB receptors in pulmonary carcinoid tumors. Clin Cancer Res 2009; 15: 3315-3324.
22. Navolanic PM, Steelman LS, McCubrey JA. EGFR family signaling and its association with breast cancer development and resistance to chemotherapy. Int J Oncol 2003; 22: 237-252.
23. Mendelsohn J. EGF receptors as a target for cancer therapy. Trans Am Clin Climatol Assoc 2004; 115: 249-253.
24. Hotta K, Kiura K, Takigawa N, et al. Paradoxical clinical effects of epidermal growth factor receptor-tyrosine kinase inhibitors for acute myelogenous leukemia. J Clin Oncol 2008; 26: 5826-5827.
25. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003; 21: 2237-2246.
26. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
27. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.